Magvanjav O, et al. - Researchers analyzed antihypertensive drug prescribing patterns, blood pressure (BP) control, and risk factors for resistant hypertension (RHTN) in a real-world setting. For this purpose, they analyzed electronic health records data from 5,658 hypertensive patients with ambulatory chronic kidney disease (CKD) who were prescribed antihypertensive therapy. Prescriptions for two-thirds of CKD patients and three-fourths of those with proteinuria comprised guideline-recommended renoprotective agents, including an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB); however, one-third were not prescribed an ACEI or ARB. Controlled BP (<140/90 mmHg) was more likely to be observed among CKD patients, particularly those with stages 1-2 CKD, who were prescribed regimens including beta-blocker (BB) + diuretic or ACEI/ARB + BB + diuretic vs those prescribed other combinations. African American race and major comorbidities were the risk factors for RHTN.